

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 December 2015 (30.12.2015)



(10) International Publication Number
WO 2015/200119 A8

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2015/036634

(22) International Filing Date:
19 June 2015 (19.06.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/017,467 26 June 2014 (26.06.2014) US

(71) Applicant: **MACROGENICS, INC.** [US/US]; 9704 Medical Center Drive, Rockville, MD 20850 (US).

(72) Inventors: **BONVINI, Ezio**; 11136 Powder Horn Drive, Potomac, MD 20854 (US). **JOHNSON, Leslie, S.**; 14411 Poplar Hill Road, Darnestown, MD 20874 (US). **SHAH, Kalpana**; 13013 Ethel Rose Way, Boyds, MD 20841 (US). **LA MOTTE-MOHS, Ross**; 111 Teachers Way #4102, Gaithersburg, MD 20877 (US). **MOORE, Paul, A.**; 7013

Old Gate Road, Bethesda, MD 20852 (US). **KOENIG, Scott**; 10901 Ralston Road, Rockville, MD 20852 (US).

(74) Agents: **KREPPEL, Lisa** et al.; Auerbachschrot LLC, 2200 Research Blvd., Suite 560, Rockville, MD 20850 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

[Continued on next page]

(54) Title: COVALENTLY BONDED DIABODIES HAVING IMMUNOREACTIVITY WITH PD-1 AND LAG-3, AND METHODS OF USE THEREOF




Figure 4

(57) Abstract: The present invention is directed to bi-specific diabodies that comprise two or more polypeptide chains and which possess at least one Epitope-Binding Site that is immunospecific for an epitope of PD-1 and at least one Epitope-Binding Site that is immunospecific for an epitope of LAG-3 (i.e., a "PD-1 x LAG-3 bi-specific diabody"). More preferably, the present invention is directed to bi-specific diabodies that comprise four polypeptide chains and which possess two Epitope-Binding Sites that are immunospecific for one (or two) epitope(s) of PD-1 and two Epitope-Binding Site that are immunospecific for one (or two) epitope(s) of LAG-3 (i.e., a "PD-1 x LAG-3 bi-specific, tetra-valent diabody").



DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

30 March 2017

Published:

— *with international search report (Art. 21(3))*

(15) Information about Correction:

see Notice of 30 March 2017